V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016323 | 160008098 | 1.17 | 84.1 | Palliative (P) | 2017-11-18 | 2017-11-24 | null | 02 | null | IPILIMUMAB + NIVOLUMAB | 101402071 |
| 160016324 | 160008099 | 1.57 | 66.2 | null | 2019-07-23 | 2019-08-19 | Bevacizumab 15mg/kg | 02 | N | FLUOROURACIL + OXALIPLATIN | 100975767 |
| 160016329 | 160008100 | null | null | Palliative (P) | 2019-02-08 | 2019-02-22 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | N | null | STS NON-RHABDO EPSSG 2005 | 100938643 |
| 160016330 | 160008101 | 1.7 | 75.2 | Palliative (P) | 2017-08-28 | 2017-09-03 | CARBOPLATIN | 02 | N | CARBOPLATIN | 100366590 |
| 160016333 | 160008102 | 1.55 | 48.6 | Curative (C) | 2017-11-02 | 2017-11-02 | STS Non-Rhabdo EpSSG 2005 Ifos Dox | 02 | N | LIPOSOMAL DOXORUBICIN | 100721169 |
| 160016340 | 160008103 | 1.63 | 67.8 | 03 | 2020-03-05 | 2020-03-20 | EW EuroEwing 2012 Arm B VDC | 02 | N | DOXORUBICIN + OLARATUMAB | 100530002 |
| 160016341 | 160008104 | 1.77 | 61.5 | null | 2020-09-23 | 2020-09-27 | Trial Unspecified | 02 | N | CISPLATIN + ETOPOSIDE | 101869418 |
| 160016342 | 160008105 | 1.51 | 70 | Neo-adjuvant (N) | 2017-02-04 | 2017-02-10 | Doxorubicin + Olaratumab | N | N | LIPOSOMAL DOXORUBICIN | 100428007 |
| 160016343 | 160008106 | 1.65 | 100.4 | Palliative (P) | 2016-04-19 | 2016-04-29 | Carboplatin + Paclitaxel (3 weekly) | 02 | null | CARBOPLATIN + PACLITAXEL | 100342353 |
| 160016345 | 160008107 | 1.72 | 81.9 | Curative (C) | 2019-06-15 | 2019-06-28 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 100784492 |
| 160016346 | 160008108 | 1.67 | 66.1 | 03 | 2019-08-01 | 2019-08-08 | CARBOPLATIN | N | N | CARBOPLATIN | 101831099 |
| 160016347 | 160008109 | 1.71 | 88 | Neo-adjuvant (N) | 2016-10-04 | 2016-10-04 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101595710 |
| 160016348 | 160008110 | 1.72 | 82 | Palliative (P) | 2017-12-04 | 2017-12-12 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100954658 |
| 160016350 | 160008111 | 1.73 | 59.8 | Palliative (P) | 2016-08-16 | 2016-08-16 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100598980 |
| 160016356 | 160008112 | 0 | 0 | 03 | 2017-07-19 | 2017-07-20 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100530545 |
| 160016357 | 160008113 | 1.73 | 80.5 | null | 2020-02-18 | 2020-02-18 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | null | IPM | 101033314 |
| 160016359 | 160008114 | 1.84 | 84.5 | Palliative (P) | 2017-03-02 | 2017-03-03 | CARBOPLATIN + ETOPOSIDE | 02 | N | PACLITAXEL | 100320153 |
| 160016361 | 160008115 | 1.79 | 87.4 | null | 2019-11-15 | 2019-11-15 | NB HRNBL-1 COJEC Ind COURSE A | 01 | N | LIPOSOMAL DOXORUBICIN | 101091128 |
| 160016362 | 160008116 | 1.73 | 71 | Palliative (P) | 2018-06-24 | 2018-06-30 | Trial Unspecified | 02 | N | OCTREOTIDE | 101279426 |
| 160016363 | 160008117 | 1.56 | 72.5 | Palliative (P) | 2016-02-17 | 2016-02-18 | Carboplatin + Paclitaxel (3 weekly) | null | null | CARBOPLATIN + PACLITAXEL | 100183842 |
| 160016365 | 160008118 | 1.55 | 85.25 | null | 2017-08-18 | 2017-09-08 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100701065 |
| 160016366 | 160008119 | 1.69 | 40.2 | Neo-adjuvant (N) | 2017-01-05 | 2017-01-06 | CARBOPLATIN + PACLITAXEL | 02 | null | CARBOPLATIN + PACLITAXEL | 101311932 |
| 160016368 | 160008120 | 1.83 | 67 | 03 | 2017-11-20 | 2017-12-02 | ETOP 13-18 BEAT-meso Trial | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101578769 |
| 160016369 | 160008121 | 1.5 | 69.7 | Palliative (P) | 2017-01-24 | 2017-02-03 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100857677 |
| 160016371 | 160008122 | 1.75 | 88.2 | Palliative (P) | 2018-03-23 | 2018-03-31 | VINORELBINE | 02 | null | CARBOPLATIN + PACLITAXEL | 101092422 |
| 160016372 | 160008123 | 1.9 | 74 | Neo-adjuvant (N) | 2016-11-24 | 2016-11-28 | OCTREOTIDE | 02 | N | CRIZOTINIB | 100418692 |
| 160016374 | 160008124 | 1.86 | 65 | Neo-adjuvant (N) | 2018-12-19 | 2019-01-03 | Pemetrexed | 02 | N | STS NON-RHABDO EPSSG 2005 IVA | 101130449 |
| 160016375 | 160008125 | null | 88 | null | 2019-06-01 | 2019-06-05 | Doxorubicin + Ifosfamide | 02 | null | DOXORUBICIN + OLARATUMAB | 100759567 |
| 160016377 | 160008126 | 1.8 | 86.4 | Neo-adjuvant (N) | 2020-02-14 | 2020-02-14 | CARBOPLATIN + PACLITAXEL | 02 | N | IFOSFAMIDE | 100775615 |
| 160016381 | 160008127 | 1.88 | 51 | Palliative (P) | 2018-09-24 | 2018-10-05 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101585770 |
| 160016388 | 160008128 | 1.7 | null | Curative (C) | 2017-10-17 | 2017-10-25 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 101042391 |
| 160016389 | 160008129 | 1.68 | 127 | Neo-adjuvant (N) | 2016-07-18 | 2016-08-14 | Cyclophosphamide oral | 02 | N | PACLITAXEL | 100501408 |
| 160016390 | 160008130 | 1.63 | 47.7 | Curative (C) | 2017-08-01 | 2017-08-05 | VINCRISTINE | 02 | N | BEVACIZUMAB + CARBO + PACLITAXEL | 100079118 |
| 160016391 | 160008131 | 1.68 | 87.2 | Neo-adjuvant (N) | 2018-06-03 | 2018-06-03 | EW EuroEwing 2012 Arm A VIDE | 02 | N | DACARBAZINE + DOXORUBICIN | 101101308 |
| 160016392 | 160008132 | 1.65 | 51.2 | Palliative (P) | 2019-06-07 | 2019-08-07 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 101645454 |
| 160016397 | 160008133 | 1.69 | 93.3 | Disease modification (D) | 2019-08-24 | 2019-08-24 | IVADo | null | N | LIPOSOMAL DOXORUBICIN | 100996157 |
| 160016399 | 160008134 | 1.63 | 63.5 | 03 | 2017-10-22 | 2017-10-22 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100864276 |
| 160016402 | 160008135 | 1.69 | 62.5 | Palliative (P) | 2019-07-03 | 2019-08-01 | CARBOPLATIN + PACLITAXEL | N | null | CARBOPLATIN + PACLITAXEL | 100789613 |
| 160016403 | 160008136 | 1.65 | 51 | null | null | 2016-08-21 | Doxorubicin 75mg/m2 | N | N | LIPOSOMAL DOXORUBICIN | 100364118 |
| 160016405 | 160008137 | 1.76 | 68 | Palliative (P) | 2016-03-01 | 2016-03-09 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 101466526 |
| 160016406 | 160008138 | 1.6 | 100.1 | Palliative (P) | 2016-02-08 | 2016-02-23 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100273028 |
| 160016407 | 160008139 | null | 74 | Curative (C) | 2016-03-20 | 2016-04-06 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 01 | N | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 101277823 |
| 160016409 | 160008140 | 1.64 | 78.8 | null | 2018-12-06 | 2018-12-06 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101579720 |
| 160016412 | 160008141 | 1.65 | 63.8 | null | 2021-02-25 | 2021-03-01 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 101739440 |
| 160016414 | 160008142 | 1.8 | 104.7 | Curative (C) | 2018-09-12 | 2018-09-19 | IVADo | 02 | N | TRIAL | 100970816 |
| 160016417 | 160008143 | 1.56 | 63.35 | Palliative (P) | null | null | Doxorubicin + Olaratumab | 01 | N | DOXORUBICIN + OLARATUMAB | 101558129 |
| 160016418 | 160008144 | 1.72 | 69.1 | Curative (C) | null | 2016-03-18 | Liposomal Doxorubicin 40mg/m2 | 02 | N | LANREOTIDE | 100563166 |
| 160016420 | 160008145 | 1.88 | 49.1 | Palliative (P) | 2019-05-18 | 2019-05-25 | Carboplatin + Etoposide iv&po | N | N | DOXORUBICIN + IFOSFAMIDE | 101362526 |
| 160016421 | 160008146 | 1.65 | 99.4 | Palliative (P) | 2018-11-05 | 2018-11-22 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 100279655 |
| 160016422 | 160008147 | 1.83 | 73.2 | Palliative (P) | 2019-12-27 | 2019-12-27 | Doxorubicin + Ifosfamide | 02 | null | LIPOSOMAL DOXORUBICIN | 100827487 |